← Evidence map

TrialClinical endocrinology2026

Impact of Osilodrostat on Health-Related Quality of Life in Cushing's Disease: Analysis of Patient-Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials.

John Newell-Price et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Impact of Osilodrostat on Health-Related Quality of Life in Cushing's Disease: Analysis of Patient-Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials. | OpenQuestion